NewTimeSpace (newtimespace.com) News: On June 15, 2026, the semiconductor concept sector in the Hong Kong stock market continued to strengthen, with the share price of ASMPT (00522.HK) pulling up substantially. As of 1:44 PM, the company's share price was quoted at HK$199.300, up 8.97%.
NewTimeSpace (newtimespace.com) News: The robotics concept sector surged as UBTECH (09880.HK) opened higher and rallied on June 15. As of 1:24 PM, the company's share price was quoted at HK$113.400, up 6.18%.
PATEO (2889.HK) and Mininglamp Technology (2718.HK) signed a strategic cooperation framework agreement. The two parties will integrate Mininglamp Technology's capabilities in AI large models, AI Agent suites, and precision marketing withPATEO's resources in edge-side hardware entry points, AI computing power infrastructure, and in-vehicle application scenarios. Together, they will build an "AI × Vehicle × User Demand" chain platform.
NewTimeSpace News: Beijing Zhipu Huazhang Technology Co., Ltd. (02513.HK) announced that it has launched its new-generation flagship model GLM-5.2. The model features a 1M long context and keeps leading performance in long-horizon tasks. It will be open-sourced under the MIT License. The model is expected to increase the call volume of the company's open platform and API business in the future.
NewTimeSpace News: Genscript Biotech Corporation (01548.HK) announced that its associate company Legend Biotech presented the first proof-of-concept clinical data of LB2501, an investigational in-vivo CD19/CD20 dual-target CAR-T cell therapy, for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphoma at the 2026 EHA Annual Meeting. At higher dose levels, the overall response rate reached 100% and the complete response rate stood at 83.3%, with all responses sustained. No dose-limiting toxicity, serious adverse events or immune effector cell-associated neurotoxicity syndrome were reported.
NewTimeSpace News: Simcere Pharmaceutical Group Limited (02096.HK) announced that SIM0689, a self-developed PD-1/VEGF-targeted bispecific antibody, has obtained the clinical trial approval notice issued by the National Medical Products Administration. Clinical trials for advanced solid tumors are planned. By relieving tumor-induced immune suppression and inhibiting angiogenesis, SIM0689 has demonstrated prominent anti-tumor efficacy even at low doses in multiple humanized mouse efficacy models.
NewTimeSpace News: Mabwell (Shanghai) Bioscience Co., Ltd. (02493.HK) announced that the Investigational New Drug (IND) application for 6MW5311 Injection in hematologic malignancies (acute myeloid leukemia, chronic myelomonocytic leukemia, and multiple myeloma) has been officially approved by the U.S. FDA. 6MW5311 is the world’s first TCE innovative drug authorized for clinical development targeting LILRB4/CD3.
NewTimeSpace News: Akeso, Inc. (09926.HK) announced that Qiyoukang® (gumokimab, AK111), a novel humanized anti-IL-17 antibody independently developed by the company, has been approved by the National Medical Products Administration (NMPA) for the treatment of moderate-to-severe plaque psoriasis. Key Phase III data showed a 12-week PASI 75 response rate of 94.6% and a PASI 100 (complete skin clearance) rate of 47.7%; the 52-week PASI 100 rate reached 68.9% with a favorable safety profile.
On June 12, Hong Kong stocks rallied, though the LLM sector experienced sharp divergence: MININGLAMP-W plummeted upward by over 21% upon completing its full-matrix edge Agentic AI deployment, and JD.com gained 3.4% on its newly unveiled A2P2 agent payment protocol, whereas MINIMAX-W tumbled 9%, halving its market value within the month. Significant infrastructure milestones were achieved globally: Visa partnered with OpenAI to establish payment and risk control mechanisms for autonomous AI agents; domestically, XUNCE allied with TuringQ to deliver an integrated "Quantum + Token OS" hardware-software solution, and Tencent Hunyuan upgraded its open-source HPC-Ops inference operators to mitigate core engineering bottlenecks.
NewTimeSpace (newtimespace.com) News: On June 12, 2026, HUA HONG GRACE (01347.HK) opened higher but subsequently retraced during morning trading. As of 14:30 PM, the company's share price was quoted at HK$141.200, up 1.36%.
Choice data shows that Mininglamp Technology-W (2718.HK) closed up 19.93% on June 11. The company's share price momentum extended into June 12, with its gain reaching 22.55% as of 13:13 PM, bringing its cumulative gain over the past two days to over 40%.
NewTimeSpace News: On June 12, 2026, BIDU-SW(09888.HK) strengthened in the morning session. As of 11:30, its share price stood at HK$114.50, up 1.24%. Apollo Go recently signed agreements for its Yangtze River Delta Supply Chain Headquarters and Regional Operation Center projects.
NewTimeSpace (newtimespace.com) News: On June 12, 2026, the humanoid robot concept stock UBTECH ROBOTICS (09880.HK) strengthened amid fluctuations during morning trading. As of 11:10 AM, the company's share price was quoted at HK$107.000, up 2.20%.
NewTimeSpace (newtimespace.com) News, on June 12, 2026, the large model concept stock Mininglamp Technology-W (2718.HK) continued to skyrocket during morning trading. As of 10:25 AM, the company's share price was quoted at HK$275.20, up 36.10%.Choice data shows that Mininglamp Technology closed up 19.93% on June 11, 2026. As of now, its cumulative gain over the past two days has exceeded 60%.
Newtimespace (newtimespace.com) reports that CStone Pharma (2616.HK) announced CS5007, an EGFR/HER3 bispecific ADC, has received HREC approval to launch its global multi-center Phase I trial, featuring the company's proprietary ADC platform with exatecan payload and CSL20 linker; AACR 2026 preclinical data demonstrated broad anti-tumor activity across multiple solid tumor CDX models, with the study targeting 310 advanced solid tumor patients across Australia and China.
NewTimeSpace News: The United Laboratories International Holdings Ltd (03933.HK) announced that TUL321 Capsule, a Class 1 innovative drug developed by its wholly-owned subsidiary Zhuhai United Laboratories Co., Ltd., has obtained the implied approval for clinical trials of new drug from the National Medical Products Administration of China. The product was approved for clinical trials by the US FDA on April 28, 2026.
